antivir
drug
gener
consider
sinc
virus
contrast
bacteria
replic
insid
cell
use
part
cellular
machineri
replic
develop
select
antivir
drug
difficult
slow
howev
situat
improv
two
decad
ago
first
viruscod
enzym
character
select
antivir
drug
idoxuridin
methisazon
amantadin
discov
compound
found
serendip
today
scientif
situat
chang
number
viru
specif
process
use
target
ration
select
design
antivir
drug
possibl
inhibit
viru
multipl
local
discret
event
viru
replic
separ
normal
cellular
function
step
briefli
discuss
chapter
detail
discuss
mechan
action
differ
inhibitor
found
later
chapter
exampl
compound
affect
herpesvirus
discuss
length
chapter
use
interferon
immunostimul
antivir
agent
briefli
describ
chapter
well
aspect
inhibit
myxo
paramyxovirus
inhibitor
viru
replic
could
either
chang
cellular
function
viru
longer
replic
could
interact
viral
function
indic
fig
latter
case
compound
could
act
directli
inhibitor
viral
enzym
eg
inhibit
herpesviru
dna
polymeras
foscarnet
activ
viral
enzym
eg
phosphoryl
acyclovir
viral
thymidin
kinas
form
compound
affect
viru
replic
case
also
cellular
function
clear
tabl
virus
induc
rna
dna
polymeras
also
enzym
use
target
antivir
compound
larg
number
author
review
function
viral
enzym
use
target
antivir
drug
kit
helgstrand
oberg
becker
swallow
chang
snydman
galasso
et
al
shannon
schabel
drach
sidwel
galasso
gordon
et
al
oxford
sugar
de
clercq
schinazi
prusoff
aspect
mention
repres
necessarili
small
use
select
consid
other
replic
dna
viru
schemat
outlin
fig
sever
distinct
step
defin
apart
differ
due
type
genom
nucleic
acid
replic
rna
viru
rather
similar
shown
fig
figur
outlin
differ
strategi
replic
posit
strand
rna
virus
neg
strand
rna
virus
retrovirus
properti
step
discuss
respect
possibl
use
target
antivir
drug
cellular
structur
respons
adsorpt
virus
call
receptor
review
see
lonbergholm
philipson
lonbergholm
phi
dimmock
function
apart
bind
viru
particl
fulli
known
exampl
histocompat
antigen
site
may
also
receptor
arbovirus
receptor
seem
compos
protein
lipid
often
polysaccharid
differ
virus
either
share
receptor
use
differ
receptor
introduct
receptor
cell
membran
cell
normal
resist
infect
make
suscept
number
receptor
viru
depend
type
viru
cell
estim
x
per
cell
polypeptid
sequenc
structur
protein
ha
influenza
viru
respons
bind
receptor
known
futur
work
area
provid
detail
inform
virus
viral
peptid
sequenc
respons
bind
receptor
possibl
prevent
influenza
viru
adsorpt
investig
use
oligopeptid
sequenc
similar
viral
protein
respons
absorpt
see
chapter
detail
oligopeptid
versu
measl
viru
advantag
type
inhibitor
act
outsid
cell
requir
penetr
cell
could
advantag
toxic
point
view
disadvantag
possibl
inhibitor
like
competit
might
requir
high
concentr
drug
also
certain
peptid
may
hydrophob
lead
problem
solubl
isol
receptor
part
could
possibl
use
antivir
agent
bind
viru
particl
thu
prevent
associ
receptor
cell
bind
site
vesicular
stomat
viru
vsv
vero
cell
character
detail
schlegel
et
al
shown
involv
phosphatidylserin
isol
phosphatidylserin
bind
vsv
particl
hsv
seem
exampl
purifi
receptor
structur
function
antivir
agent
plaqu
format
vsv
reduc
pm
phosphatidylserin
virus
myxovirus
paramyxovirus
need
fuse
cellular
membran
stage
life
cycl
process
seem
ph
depend
involv
haemagglutinin
ha
fusion
f
protein
respect
lysosomotrop
compound
amantadin
could
possibl
act
increas
ph
thu
prevent
low
ph
fusion
subsequ
infect
import
approach
could
give
inhibitor
fairli
broad
rang
antivir
specif
even
though
effect
cell
function
antivir
activ
take
place
concentr
prohibit
toxic
uninfect
cell
combin
techniqu
genet
engin
rapid
dna
sequenc
result
extens
new
data
amino
acid
sequenc
influenza
protein
earli
seri
experi
porter
et
al
clone
gene
code
import
haemagglutinin
ha
protein
influenza
viru
insert
dna
copi
e
coli
plasmid
rapid
dna
sequenc
techniqu
allow
determin
complet
nucleotid
sequenc
ha
molecul
classic
studi
extend
appli
ha
influenza
virus
appar
inspect
amino
acid
sequenc
ha
virus
unrel
antigen
h
viru
isol
see
chapter
certain
short
amino
acid
stretch
conserv
year
period
wherea
rest
molecul
complet
differ
review
laver
et
al
might
impli
common
import
function
short
common
sequenc
resembl
amino
acid
sequenc
fusion
f
protein
paramyxoviru
sendai
led
suggest
sequenc
n
terminu
polypeptid
influenza
ha
similar
function
name
fusion
cell
membran
allow
exit
nucleic
acid
viru
entri
cell
nucleu
quit
separ
biolog
experi
white
et
al
establish
low
ph
condit
influenza
virus
could
lyse
red
blood
cell
caus
fusion
tissu
cultur
cell
richardson
et
al
synthes
short
peptid
zglyleulphegli
zglylphelphegli
mimick
sequenc
n
terminu
polypeptid
describ
rel
low
concentr
pm
peptid
inhibit
influenza
viru
replic
tissu
cultur
studi
see
chapter
possibl
short
peptid
act
vivo
antivir
milieu
proteolyt
enzym
would
seem
remot
may
possibl
synthes
analogu
add
group
prevent
rapid
enzym
digest
vivo
biochem
studi
also
rais
basic
question
mode
action
amantadin
sinc
compound
act
earli
infect
inhibit
viru
fusion
interpret
data
even
complic
result
recent
studi
richman
et
al
demonstr
quit
clearli
although
amantadin
taken
rapidli
tissu
cultur
cell
less
rapidli
lost
cell
incub
amantadinefre
medium
hand
antivir
action
lost
almost
immedi
cell
place
drug
free
medium
suggest
intracellular
amantadin
littl
effect
antivir
state
perhap
interact
amantadin
extern
surfac
plasma
membran
could
explain
antivir
action
amantadin
belong
class
compound
term
lysosomotrop
increas
intralysosom
ph
pool
ohkuma
fusion
import
stage
influenza
viru
replic
fusion
occur
low
ph
cytoplasm
vacuol
still
possibl
amantadin
could
act
rais
intravacuolar
ph
thu
stop
fusion
block
viru
replic
stage
similarli
complet
sequenc
neuraminidas
na
gene
influenza
determin
clone
dna
copi
gene
bacteriophag
field
et
al
antineuraminidas
antibodi
inhibit
viral
replic
also
specif
inhibitor
na
henc
enzym
suitabl
target
chemotherapi
review
pales
schulman
sequenc
na
protein
conserv
independ
antigen
drift
short
oligopeptid
could
synthes
inhibitori
effect
investig
describ
ha
protein
rna
code
na
protein
nucleotid
long
includ
nucleotid
first
aug
nucleotid
last
codon
one
read
frame
open
begin
aug
posit
two
read
frame
block
termin
codon
predic
na
protein
colinear
rna
occupi
code
capac
gene
thu
gene
code
singl
protein
major
hydrophob
region
locat
near
nterminu
residu
two
human
subtyp
total
conserv
first
amino
acid
describ
thu
critic
role
interact
anoth
viru
protein
na
subunit
might
anticip
short
sequenc
na
polypeptid
may
extend
signal
sequenc
respons
transfer
na
protein
across
membran
remain
bilay
anchor
na
altern
rel
new
approach
search
influenza
viru
inhibitor
synthes
compound
compet
viru
receptor
bind
site
cell
earlier
studi
cell
surfac
receptor
paramyxovirus
indic
import
sialic
acid
cell
surfac
oligosaccharid
sinc
sialidas
treatment
host
cell
prevent
viru
infect
recent
studi
shown
host
cell
receptor
sendai
viru
complex
specif
gangliosid
act
host
cell
receptor
holmgren
et
al
experiment
approach
markwel
et
al
remov
cell
receptor
sendai
viru
mdbk
cell
sialidas
incub
cell
individu
highli
purifi
gangliosid
determin
mdbk
cell
regain
suscept
viru
absorpt
infect
incub
cell
gangliosid
contain
sequenc
gal
gal
nac
fulli
restor
suscept
infect
cell
gangliosid
sequenc
end
two
sialic
acid
linkag
instead
singl
sialic
acid
time
effect
receptor
gangliosid
certain
polysialo
gangliosid
induc
cellcel
fusion
incub
cell
one
could
specul
attach
sendai
viru
cell
surfac
may
stabil
cluster
receptor
molecul
facilit
viruscel
fusion
markwel
et
al
viru
cell
fusion
demonstr
central
event
infect
process
para
myxovirus
search
fusion
inhibitor
could
result
broad
spectrum
antivir
molecul
certain
diamidin
shown
recent
inhibit
fusion
respiratori
syncyti
viru
dubovi
et
al
dubovi
et
al
approach
would
ad
attract
influenza
fusion
sequenc
common
mani
antigen
subtyp
thu
potenti
allow
broad
spectrum
antivir
activ
compar
receptor
bind
site
studi
report
influenza
viru
recent
work
addit
emphas
phenotyp
divers
virus
discuss
detail
carrol
et
al
see
chapter
thu
author
examin
absorpt
red
blood
cell
two
strain
influenza
viru
r
l
j
two
virus
found
total
differ
specif
bind
gal
gal
linkag
respect
examin
crystal
structur
ha
show
host
cell
receptor
cleft
distinct
antigen
site
wiley
et
al
variat
receptor
specif
could
aris
natur
select
pressur
host
specifi
sialyloligosaccharid
present
cell
surfac
glycoprotein
case
inhibitor
receptor
function
might
rather
specif
mutant
circumv
activ
might
easili
aris
virus
code
n
andor
rna
polymeras
shown
tabl
virus
also
induc
format
enzym
involv
synthesi
nucleosid
nucleotid
use
degrad
r
n
dna
detail
enzym
given
respect
chapter
discuss
differ
virus
major
antivir
drug
found
recent
year
use
viral
enzym
involv
nucleic
acid
synthesi
target
viral
enzym
involv
format
nucleosid
nucleotid
list
tabl
use
antivir
drug
yet
found
affect
use
ribonucleotid
reductas
deoxycytidin
deaminas
enzym
futur
explor
detail
respect
possibl
use
select
activ
drug
hsv
ribonucleotid
reductas
well
character
might
requir
viru
replic
effect
nucleosid
analogu
triphosph
cellular
hsv
ribonucleotid
reductas
studi
bvdutp
exampl
show
select
inhibit
viral
enzym
nakayama
et
al
nucleosid
kinas
enzym
requir
phosphoryl
nucleosid
nucleosid
monophosph
found
viru
infect
cell
especi
member
herpesviru
famili
indic
tabl
seem
gener
properti
viru
induc
thymidin
kinas
pyrimidin
kinas
less
strict
structur
requir
substrat
similar
cell
enzym
compound
acyclovir
elion
et
al
dhbg
larsson
et
al
bvdu
cheng
et
al
phosphoryl
viral
kinas
cell
thymidin
kinas
thu
lead
select
activ
viru
infect
cell
phosphoryl
competit
reaction
influenc
concentr
thymidin
larsson
et
al
phosphoryl
nucleosid
monophosph
diand
triphosph
seem
carri
cellular
enzym
competit
reaction
might
import
final
concentr
nucleosid
triphosph
larg
number
pyrimidin
analogu
found
phosphoryl
herpesviru
thymidin
kinas
discuss
later
chapter
herpesviru
inhibitor
shown
tabl
exampl
differ
phosphoryl
cytosol
viral
kinas
obviou
enzym
substrat
specif
resembl
viral
enzym
phosphoryl
purin
analogu
mediat
cellular
enzym
note
acycl
guanosin
analogu
recogn
tk
pyrimidin
phosphoryl
monophosph
seem
regard
purin
monophosph
phosphoryl
g
p
kinas
sinc
virus
induc
format
n
andor
rna
polymeras
see
tabl
substanti
amount
work
direct
toward
find
select
inhibitor
viral
polymeras
gener
polymeras
inhibitor
could
bind
differ
site
polymeras
compet
sugar
base
triphosph
bind
site
affect
site
pyrophosph
split
polymer
current
known
inhibitor
list
tabl
triphosph
nucleosid
analogu
seem
act
competit
inhibitorssubstr
exemplifi
araatp
miiller
et
al
acyclovir
triphosph
furman
et
al
ders
et
al
bvdu
triphosph
allaudeen
et
al
ruth
pyrophosph
analogu
foscarnet
paa
act
non
uncompetit
inhibitor
see
boezi
eriksson
oberg
oberg
kinet
paramet
nucleosid
analogu
triphosph
shown
tabl
togeth
k
valu
compet
substrat
earlier
studi
sever
seri
molecul
react
virion
associ
rn
transcriptas
enzym
influenza
viru
synthes
semilog
basi
common
mani
dna
polymeras
enzym
influenza
enzym
might
zinc
metalloenzym
compound
synthes
could
bind
revers
zinc
would
bound
revers
firmli
enzymethi
zinc
metalloenzym
hypothesi
perrin
stunzi
compound
good
zinc
chelat
activ
pyridin
thiosemicarbazon
selenocystamin
mark
inhibitori
effect
virion
associ
rna
transcriptas
enzym
number
influenza
b
virus
howev
compound
detect
activ
cell
subsequ
helgstrand
oberg
use
influenza
rna
transcriptas
enzym
test
basi
base
sugar
modif
bvarau
flac
al
u
hpuara
acg
note
nucleosid
analogu
inhibitor
triphosph
extens
vitro
screen
inhibitori
molecul
compound
activ
inhibitor
polymeras
also
shown
antiinfluenza
activ
cell
stridh
et
al
sinc
influenza
viru
uniqu
possess
cap
recogn
protein
rna
transcriptas
complex
kroath
shatkin
could
provid
addit
target
select
inhibitor
clone
studi
alreadi
progress
sever
laboratori
eventu
delin
rna
transcriptas
enzym
bind
site
rna
data
may
enabl
synthesi
specif
inhibitor
recent
studi
sequenc
specif
contact
vesicular
stomati
viru
vsv
rna
polymeras
leader
rna
gene
may
therefor
provid
model
approach
keen
et
al
rna
polymeras
complex
vsv
consist
l
ns
n
protein
sinc
transcript
start
terminu
rna
assum
promot
polymeras
resid
leader
gene
author
util
methyl
protect
studi
sequenc
specif
interact
vsv
rna
n
protein
render
rna
resist
nucleas
although
alter
reactiv
rna
methyl
dimethyl
sulphat
alkyl
agent
bind
polymeras
l
ns
protein
nucleocapsid
examin
ns
protein
present
reactiv
rna
dimethyl
sulphat
alter
middl
leader
gene
thu
ns
may
function
initi
protein
transcript
recogn
bind
specif
site
genom
ns
protein
bind
sequenc
ribavirin
triphosph
shown
inhibit
influenza
rna
polymeras
cellfre
assay
eriksson
et
al
unclear
extent
import
vivo
attempt
made
use
oligonucleotid
complementari
viral
dna
rna
inhibitor
result
differ
differ
virus
rather
extend
size
oligonucleotid
capabl
stabl
specif
basepair
make
penetr
cell
difficult
clear
whether
viral
rna
freeli
access
basepair
zamecnik
stephenson
stridh
et
al
smith
et
al
stridh
et
al
describ
rna
transcriptas
inhibitori
activ
certain
polynudeotid
common
experi
describ
molecul
inhibit
wide
rang
influenza
b
virus
inde
mark
featur
inhibitor
sinc
far
known
minim
genet
variat
occur
viru
p
np
polypeptid
influenza
virus
togeth
consid
constitut
rna
transcriptas
enzym
activ
smith
et
al
calcul
inhibit
influenza
rna
transcriptas
activ
occur
molecul
per
rna
molecul
inhibit
probabl
involv
direct
bind
transcriptas
enzym
howev
polynucleotid
compound
mild
antivir
activ
vivo
potter
et
al
difficult
assess
presenc
nucleas
purifi
viru
prepar
contamin
cellular
enzym
often
possibl
case
viru
induc
nucleas
identifi
part
viral
polymeras
select
viru
induc
associ
nucleas
present
tabl
dnase
activ
associ
hsvi
dna
polymeras
inhibit
foscarnet
ders
cheng
interestingli
activ
cleavag
dinucleotid
contain
one
toxic
nucleosid
suggest
way
util
viral
nucleas
target
antivir
drug
inhibit
cap
depend
endonucleas
activ
influenza
viru
ulmanen
et
al
constitut
logic
point
attack
antivir
drug
prevent
util
cellular
mrna
cap
viral
polymeras
viral
infect
often
result
shutoff
cellular
protein
synthesi
viru
mrna
use
cellular
compon
initi
factor
ribosom
rna
synthesi
viral
polypeptid
effect
antivir
drug
describ
interfer
step
cleavag
viral
polypeptid
common
event
case
picornavirus
cleavag
mediat
viru
code
proteas
addit
cleavag
influenza
haemagglutinin
polypeptid
ha
ha
necessari
viral
infect
possibl
target
block
antivir
drug
littl
publish
area
sequenc
determin
cleavag
pattern
viral
polypeptid
becom
clear
like
mean
inhibit
cleavag
found
use
proteas
inhibitor
influenza
replic
report
zhirnov
et
al
butterworth
korant
review
process
viral
polyprotein
viral
protein
sever
import
posttransl
event
glycosyl
phosphoryl
viral
polypeptid
occur
compound
dglucoseamin
interfer
glycosyl
inhibit
multipl
influenza
herpesviru
compound
studi
far
result
antivir
drug
therapeut
activ
vivo
import
correct
phosphoryl
viral
protein
way
regul
function
shown
virus
influenza
also
shown
collett
erikson
function
src
gene
avian
sarcoma
viru
protein
kinas
sever
virus
corona
viru
siddel
et
al
polyoma
viru
smith
et
al
report
contain
protein
kinas
function
remain
larg
unclear
inhibitor
viral
protein
phosphoryl
protein
kinas
report
yet
like
come
futur
earli
judg
potenti
use
compound
interf
protein
phosphoryl
possibl
antivir
drug
context
note
one
function
interferon
induc
protein
kinas
phosphoryl
impair
activ
peptid
chain
initi
factor
thu
inhibit
protein
synthesi
see
lengyel
assembl
viral
nucleic
acid
viral
protein
process
appear
distinct
known
cellular
function
clearcut
inhibitor
viral
assembl
report
influenza
neuraminidas
implic
releas
dispers
new
viru
particl
pales
schulman
sever
inhibitor
influenza
neuraminidas
fana
pales
et
al
describ
activ
cell
cultur
infect
anim
pales
schulman
could
fertil
area
futur
work
virucid
compound
direct
destruct
effect
intact
viru
particl
seem
toxic
also
cell
attempt
find
antivir
select
present
time
resort
pure
trial
error
virucid
compound
penetr
cell
could
possibl
lower
henc
select
toxic
distribut
affect
organ
might
restrict
unfortun
point
view
approach
spread
viru
one
cell
anoth
could
take
place
without
viru
expos
extracellularli
case
herpesvirus
certain
paramyxovirus
butyl
hydroxytoluen
might
act
virucid
agent
disrupt
herpesvirus
even
infect
anim
keith
et
al
viral
genom
integr
cellular
genom
replic
viral
genom
probabl
mediat
cellular
enzym
sever
restrict
possibl
elimin
viru
host
cell
exampl
type
integr
retrovirus
probabl
hepat
b
viru
chronic
infect
papilloma
wart
howev
viral
enzym
express
could
use
select
activ
compound
transform
toxic
entiti
thu
affect
cell
possess
viral
genom
howev
compound
report
activ
situat
case
latent
infect
viral
genom
integr
possibl
slow
viral
multipl
take
place
repres
possibl
target
antivir
compound
develop
anim
latent
infect
caus
hsvi
affect
antiherp
drug
block
viral
replic
major
problem
lack
data
concern
state
latent
herp
simplex
viru
exist
ganglia
elsewher
reactiv
steven
klein
search
antivir
drug
larg
number
compound
test
differ
cell
anim
model
major
part
test
seem
util
cell
cultur
infect
influenza
herp
rhino
viru
interest
target
antivir
chemotherapi
case
antivir
effect
observ
cell
cultur
follow
therapeut
effect
infect
anim
illustr
wide
rang
compound
show
antivir
efficaci
cell
cultur
select
structur
compil
tabl
interferon
immunomodul
discuss
separ
compound
discuss
detail
later
chapter
other
probabl
futur
antivir
drug
could
serv
use
start
point
search
better
compound
might
requir
evalu
mode
action
indic
one
step
although
could
sever
reaction
affect
limit
number
refer
includ
compound
discuss
review
antivir
drug
refer
begin
chapter
possibl
use
interferon
clinic
either
prophylact
therapeut
limit
long
time
small
amount
interferon
avail
dna
hybrid
technolog
situat
chang
larg
control
trial
use
interferon
becom
feasibl
situat
time
complic
find
sever
differ
human
interferon
need
analyz
differ
interferon
combin
interferon
antivir
activ
man
tabl
list
three
main
type
human
interferon
also
indic
sever
differ
speci
within
one
type
interferon
origin
cell
enough
defin
type
speci
interferon
interferon
first
detect
isaac
lindenmann
antivir
action
cell
cultur
synthesi
interferon
cell
induc
number
agent
virus
bacteria
nucleic
acid
mitogen
etc
sever
interferon
induc
investig
polynucleotid
poli
poli
c
polym
rather
high
toxic
low
molecular
weight
interferon
induc
develop
n
ndioctadecyln
nbi
carboxyethylgermanium
sesquioxid
tiloron
pyrimidol
induc
interferon
reach
cell
exert
number
function
schemat
illustr
fig
see
lengyel
rel
import
differ
pathway
interferon
action
known
induct
fig
seem
central
role
antivir
activ
synthesi
one
cellular
enzym
induc
interferon
laurent
et
al
balanc
degrad
interferon
induc
enzym
result
activ
latent
ribonucleas
rnase
l
degrad
mrna
rrna
viral
rna
sinc
rather
labil
effort
made
synthes
analogu
intend
stabl
activ
rnase
l
sever
structur
analogu
synthes
intent
epstein
et
al
kwiatkowski
et
al
sawai
et
al
haugh
et
al
interest
approach
increas
stabil
obtain
modifi
still
compound
molecular
weight
high
easi
penetr
cell
activ
area
research
present
improv
compound
expect
use
would
presum
broad
rang
drug
rna
virus
unclear
present
suffici
virusspecif
nontox
cell
overal
et
al
determin
interferon
concentr
herp
vesicl
human
found
high
gener
interferon
product
viru
infect
tissu
quantit
limit
knowledg
actual
optim
level
interferon
tissu
viral
infect
make
difficult
predict
therapeut
efficaci
exogen
given
interferon
obviou
possibl
interferon
prophylact
drug
assum
toxic
accept
studi
therapeut
prophylact
use
interferon
present
follow
chapter
type
viru
infect
reader
judg
himherself
clinic
use
interferon
review
dunnick
galasso
galasso
tabl
list
clinic
trial
use
interferon
case
limit
number
patient
preclud
evalu
clinic
efficaci
seem
like
hope
interferon
would
turn
new
wonder
drug
grossli
exagger
howev
like
situat
use
prophylaxi
therapi
probabl
also
combin
antivir
drug
possibl
modul
natur
immun
respons
obviou
way
develop
antivir
agent
rapid
progress
understand
immunolog
process
make
like
futur
possibl
design
compound
therapeut
prophylact
efficaci
viral
infect
howev
compound
test
far
levamisol
inosiplex
shown
littl
effect
mechan
action
levamisol
increas
phagocytosi
cellmedi
immun
respons
polymorphonuclear
leukocyt
chemotaxi
use
herp
papilloma
infect
seem
doubt
russel
might
van
eygen
et
al
inosiplex
isoprinison
seem
restor
tlymphocyt
function
depress
viral
infect
possibl
also
augment
interferon
action
werner
use
inosiplex
present
unclear
await
doubleblind
placebocontrol
trial
chang
heel
editori
lancet
combin
immunomodul
select
antivir
drug
possibl
explor
problem
drug
deliveri
uniqu
antivir
drug
novel
charact
littl
data
report
exampl
like
topic
applic
herpet
infect
pose
penetr
problem
dri
skin
mucou
membran
cornea
eye
also
like
vehicl
method
applic
could
import
drug
use
gener
problem
need
use
antivir
drug
onset
infect
often
rapid
cours
diseas
requir
rapid
diagnosi
prefer
direct
deliveri
medic
affect
skin
topic
applic
infect
upper
airway
aerosol
correct
diagnosi
patient
appropri
drug
hand
goal
far
rapidli
progress
viral
diseas
like
cold
sore
genit
herp
common
cold
influenza
concern
infect
prolong
cours
viru
replic
immunocompromis
patient
might
easier
target
antivir
drug
spite
limit
use
antivir
drug
far
concern
express
possibl
develop
drug
resist
field
wildi
problem
concern
druginduc
resist
recent
review
field
discuss
detail
chapter
clear
use
antivir
drug
cell
cultur
result
select
drug
resist
viru
equal
clear
select
drug
resist
bacteria
rapid
process
perhap
surprisingli
sinc
replic
time
viru
order
sever
hour
bacteria
less
half
hour
certainli
impli
penicillin
use
indiscrimin
also
concern
viru
resist
exagger
protocol
term
observ
widespread
use
amantadin
rimantadin
ussr
result
develop
resist
although
resist
virus
report
gdr
heider
et
al
case
recurr
diseas
labial
genit
herp
clear
whether
possibl
develop
resist
one
episod
diseas
result
emerg
resist
viru
next
episod
gener
herp
infect
immunocompromis
patient
long
term
system
treatment
result
develop
resist
acyclovir
sibrack
et
burn
et
al
crumpack
et
al
wade
et
al
situat
clearli
differ
treatment
local
recurr
herp
diseas
immunolog
normal
person
develop
drug
resist
becom
problem
herp
infect
remain
possibl
combin
drug
differ
mode
action
thu
decreas
risk
resist
strain
becom
establish
develop
antivir
drug
start
cell
cultur
experi
determin
inhibit
viru
multipl
vitro
method
certain
advantag
low
cost
eas
use
howev
give
quit
mislead
result
substrat
analogu
exampl
investig
sinc
often
competit
inhibitor
activ
reaction
compet
natur
substrat
natur
substrat
higher
concentr
infect
human
organ
cell
cultur
compound
lower
efficaci
infect
organ
cell
cultur
also
possibl
experi
anim
cell
intact
anim
could
mislead
exampl
phosphoryl
antivir
drug
involv
cellular
enzym
could
speci
differ
substrat
specif
present
would
agre
combin
use
cellfre
assay
system
cell
cultur
anim
model
seem
requir
make
reason
predict
clinic
efficaci
antivir
exampl
type
correl
differ
level
analysi
shown
tabl
lack
correl
cell
cultur
anim
experi
possibl
could
explain
differ
affin
thymidin
kinas
nucleosid
analogu
presenc
thymidin
guinea
pig
skin
harmenberg
forscarnet
hand
unaffect
thymidin
antivir
drug
appear
pass
clinic
test
fair
conclud
better
posit
predict
efficaci
futur
drug
number
antivir
drug
tri
far
proper
doubleblind
placebocontrol
clinic
trial
still
small
precis
correl
preclin
clinic
efficaci
develop
antivir
drug
drug
long
process
first
part
outlin
fig
stepwis
evalu
modif
structur
optim
antivir
activ
indic
programm
screen
evalu
start
use
inhibit
viru
multipl
cell
cwlture
instanc
screen
start
anim
model
differ
viral
diseas
case
mechan
action
analyz
vivo
effect
found
viral
enzym
target
screen
use
cellfre
enzym
first
step
way
hope
ration
defin
mechan
action
start
possibl
specifi
precis
time
resourc
requir
newli
start
project
find
compound
activ
viru
infect
year
reason
estim
virus
herpesvirus
number
activ
inhibitor
alreadi
known
task
simpler
find
inhibitor
viru
influenza
activ
inhibitor
report
inform
inact
structur
help
search
activ
inhibitor
unfortun
mostli
activ
inhibitor
report
scientif
literatur
compound
test
found
inact
screen
programm
thorough
evalu
celltox
properti
carri
anim
experi
start
stenberg
procedur
consider
number
toxic
inhibitor
elimin
earli
stage
reduc
number
anim
experi
requir
advantag
ethic
econom
point
view
also
point
human
cell
use
studi
evalu
inhibitor
regist
drug
outlin
fig
actual
scheme
specif
drug
could
deviat
consider
fig
time
effort
involv
probabl
less
evalu
outlin
fig
toxic
problem
step
involv
restart
synthesi
new
compound
safeti
evalu
anim
expens
realiz
anim
studi
model
first
human
trial
limit
number
volunt
care
monitor
advers
effect
evalu
clinic
efficaci
human
larg
difficult
part
develop
antivir
drug
number
uncontrol
clinic
studi
claim
efficaci
differ
drug
viral
diseas
depressingli
larg
essenti
perform
doubleblind
placebocontrol
statist
well
evalu
studi
abl
judg
clinic
efficaci
antivir
drug
praiseworthi
high
standard
respect
shown
studi
carri
us
nation
institut
allergi
infecti
diseas
niaid
programm
antivir
substanc
studi
could
mani
respect
serv
guidelin
proper
clinic
evalu
especi
antiherp
drug
see
chapter
detail
knowledg
detail
natur
histori
molecular
biolog
viral
diseas
virus
increas
obvious
better
opportun
find
new
drug
method
xray
diffract
measur
nmr
determin
probabl
lead
detail
understand
structur
interact
take
place
activ
site
viral
enzym
cellular
counterpart
could
hope
result
ration
comput
aid
design
compound
high
select
viral
enzym
also
need
detail
insight
natur
histori
viral
diseas
abl
choos
right
approach
inhibit
develop
rapid
diagnosi
viral
infect
import
complement
develop
new
antivir
drug
ideal
method
make
correct
diagnosi
possibl
within
half
hour
sensit
method
use
immunolog
principl
monoclon
antibodi
nucleic
acid
hybrid
develop
requir
simplif
gener
access
final
develop
antivir
drug
uncommon
viral
diseas
like
pursu
pharmaceut
compani
econom
reason
could
appear
spinoff
product
search
drug
common
diseas
import
area
intern
agenc
countri
consid
costbenefit
analysi
develop
antivir
drug
consider
turn
favour
develop
drug
actual
research
work
probabl
effici
carri
contract
exist
pharmaceut
compani
institut
type
arrang
tri
date
antivir
drug
obviou
applic
viru
infect
develop
countri
well
rare
infect
industri
world
iron
also
possibl
less
secret
develop
antivir
agent
virus
potenti
use
biolog
warfar
militari
import
could
result
therapi
infect
yellow
fever
japanes
b
enceph
togaviru
infect
